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ABSTRACT
BACKGROUND. Chlamydia trachomatis is the most common sexually transmitted pathogen
in adults, which at delivery may be transmitted from mother to child and cause
conjunctivitis and pneumonia. In the Netherlands, prenatal chlamydial screening
and treatment of pregnant women is not routine practice. The contribution of C
trachomatis to neonatal ophthalmic disease has not been studied in the Netherlands
and remains unclear.
METHODS. At the Sophia Children’s Hospital and Rotterdam Eye Hospital, 2 cohorts of
infants 3 months of age presenting with conjunctivitis were studied, 1 retrospec-
tively (July 1996 to July 2001) and 1 prospectively (September 2001 to September
2002). Laboratory diagnosis was based on bacterial culture and polymerase chain
reaction for C trachomatis.
RESULTS. C trachomatis was detected in 27 (64%) of 42 retrospectively studied infants
and 14 (61%) of 23 prospectively studied infants. Mucopurulent discharge was
present in 35 (95%) of 37, swelling of the eyes in 27 (73%) of 37, conjunctival
erythema in 24 (65%) of 37, respiratory symptoms in 14 (38%) of 37, and feeding
problems in 5 (14%) of 37 infants respectively. Before microbiological diagnosis,
general practitioners prescribed antichlamydial antibiotics locally to 5 (12%) of 41
and systemically to 4 (10%) of 41 infants who tested positive for chlamydia, and
ophthalmologists prescribed to 21 (51%) of 41 and 7 (17%) of 41, respectively.
CONCLUSIONS. C trachomatis was the major cause of bacterial conjunctivitis in this pop-
ulation. Clinically, differentiation from other pathogens was not possible. Many
infants who tested positive for chlamydia did not receive appropriate antibiotic
treatment.
THE OCCURRENCE OF Chlamydia trachomatis infection in infants is directly related tothe prevalence of maternal urogenital infections and vertical transmission
rates.1–4 The overall risk for infants born to women with untreated chlamydial
infection is 50% to 75%, with infection occurring at 1 anatomic site. Conjunc-
tivitis may occur in 20% to 50% of infected infants, nasopharyngitis in 70%, and
pneumonia in 5% to 20%.5 C trachomatis has become the most frequent identifiable
cause of neonatal conjunctivitis in many countries.6–9 The majority of chlamydial
conjunctivitis cases heal spontaneously during the first few months of life. However, untreated persistent infections
can lead to acute discomfort and distress for both infant and mother, as well as to chronic eye disease. Simultaneous
silent infection of the respiratory tract may cause acute or chronic respiratory disease.3,10,11
Screening of pregnant women for C trachomatis infection was recommended by the Centers for Disease Control and
Prevention more than a decade ago.12,13 In 2004 the Dutch National Health Council advised against routine
chlamydial screening of Dutch pregnant women, because local data with respect to chlamydial infection in pregnant
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women and the contribution of C trachomatis to neonatal
disease (pregnancy outcome, conjunctivitis, and respira-
tory tract infection) provided insufficient evidence to
support screening.14,15 Recently we reported a prevalence
of C trachomatis infection in pregnant women of 6.4%.16
Most of these infections had been missed in routine care,
suggesting that C trachomatis transmission to infants may
often remain unnoticed.
The main objective of this study was to establish
whether C trachomatis was a cause of neonatal conjunc-
tivitis in infants referred to hospital-based care in Rot-
terdam, the second largest city in the Netherlands. In
addition, we evaluated the clinical presentation of and
prescribed treatment for chlamydial conjunctivitis com-
pared with other infections.
MATERIALS ANDMETHODS
Study Population
We conducted our study at the Rotterdam Eye Hospital
(REH) and Sophia Children’s Hospital (SCH) of the Eras-
mus University Medical Centre (Rotterdam, Nether-
lands). Rotterdam has a multiethnic population. Chla-
mydial screening is not standard practice in pregnant
women in the study area; testing is done on clinical
suspicion. Neonatal ocular prophylaxis against chla-
mydia or gonorrhoea is not routinely provided. Most
newborns with conjunctivitis are treated at mother and
child health clinics or by general practitioners (GPs).
Infants with persistent conjunctivitis are referred to the
REH or SCH depending on the parents’ or referring GP’s
choice. We studied infants retrospectively between July
1996 and July 2001 and prospectively between Septem-
ber 2001 and September 2002. Infants3 months of age
presenting to the REH or SCH with bacterial (mostly
persistent) conjunctivitis were eligible for the study. We
defined bacterial conjunctivitis as having conjunctival
erythema, swelling of the eyelids, and/or mucopurulent
discharge. In the retrospective study, infants who were
diagnosed by ophthalmologists with viral conjunctivitis
(conjunctival erythema only) and who were neither
microbiologically tested nor treated with antibiotics and
improved spontaneously were excluded from the study.
Similarly, infants with dacryostenosis (nasolacrimal duct
obstruction) were excluded from the study. Infants di-
agnosed with chlamydial conjunctivitis in the REH were
referred to the SCH for further investigation and sys-
temic treatment. Infants diagnosed with C trachomatis
conjunctivitis in our prospective study were treated sys-
temically with erythromycin suspension (ethylsucci-
nate), 50 mg/kg per day, in 3 to 4 oral doses for 10 to 14
days and were invited for a single follow-up visit. Par-
ents were asked to return to the clinic if the infant had
respiratory symptoms. Parents themselves were referred
to the sexually transmitted disease clinic for investiga-
tion and treatment.
Microbiological Diagnosis
Eye swabs were taken for routine bacterial culture,
including gonococcal culture, and chlamydial and gono-
coccal polymerase chain reaction (PCR) (Cobas Ampli-
cor, Roche Molecular Diagnostics, Pleasanton, CA).
Specimens were obtained by swabbing the conjunctiva
of the everted lower eyelid using a sterile Dacron swab.
Bacteriologic cultures were processed according to stan-
dard procedures for aerobic bacteria in a clinical micro-
biology laboratory. Chlamydial and gonococcal PCRs
were performed according to the manufacturer’s in-
structions.
Treatment
Antibiotics that were prescribed and considered to be
effective against C trachomatis were erythromycin,
azithromycin, clarithromycin, tetracycline and doxycy-
cline, and chloramphenicol.
Data Collection
We collected retrospective data through a systematic
review of medical charts. We used a standardized ques-
tionnaire and laboratory investigations to collect pro-
spective data. Recorded variables included the following:
age at presentation, gender, complaints (conjunctival
erythema, swelling of the eyelids, mucopurulent dis-
charge, unilateral/bilateral involvement, and respiratory
or feeding problems), physical examination, diagnostic
tests, diagnosis, and therapy by GPs and ophthalmolo-
gists before microbiological diagnosis.
Statistical Analysis
We used SPSS 10.0.0 (SPSS Inc, Chicago, IL) for our
analyses. We used uncorrected 2 tests to compare cat-
egorical variables. We calculated risk ratios (with 95%
confidence intervals) to examine factors associated with
a diagnosis of chlamydia conjunctivitis.
RESULTS
Demographics
Retrospectively, 64 infants with conjunctivitis were
identified; 36 (56%) were boys. The median age was 2
weeks, with a range of 0 to 13 weeks. Prospectively, 23
infants were enrolled; 12 (52%) were boys. The median
age was 1 week, with a range of 0 to 7 weeks.
Diagnostic Tests
Five of 64 retrospectively studied infants were clinically
diagnosed with bacterial conjunctivitis without perform-
ing a laboratory test. The remaining 59 infants had a
bacterial culture done, including gonococcal culture; 42
infants also had a chlamydial PCR, and 17 infants had a
gonococcal PCR. With inclusion of all of the tests, 50
(85%) of 59 tested infants had a positive result. All 23 of
the prospectively studied infants had bacterial and gono-
coccal cultures done, as well as a chlamydial and gono-
coccal PCR. Nineteen infants (83%) had a pathogen
detected. Table 1 shows the frequency of isolated species.
Detection of C trachomatis was significantly higher than
of other pathogens (P  .001), with similar rates in
retrospectively and prospectively studied infants: 27
(64%) of 42 and 14 (61%) of 23, respectively. Three
infants in the retrospective cohort with Haemophilus in-
fluenzae had a second pathogen diagnosed.
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Clinical Presentation
We examined the age of 69 infants with microbiologically
confirmed conjunctivitis. Of these infants, 41 had chla-
mydial conjunctivitis and 28 had another infection (Table
2). Infants with chlamydial conjunctivitis were 2.3 times
(95% confidence interval: 1.0–5.2 times) more likely than
those with other infections to present between 1 and 6
weeks of age than within the first week of life. We were
able to examine clinical information in 37 infants with
chlamydial conjunctivitis (23 diagnosed retrospectively
and 14 prospectively) and 22 with another pathogen (17
diagnosed retrospectively and 5 prospectively). Because
there was no significant difference between the retrospec-
tive and prospective study, and the number of infants in
each study was small, the overall results of a total of 37
evaluable infants who tested positive for chlamydia and 22
infants with another pathogen are shown in Table 2. Mu-
copurulent discharge was the presenting symptom for 35
(95%) of 37 infants who tested positive for chlamydia,
swelling of the eyelids for 27 (73%) of 37, and conjunctival
erythema for 24 (65%) of 37 compared with 22 (100%) of
22, 11 (50%) of 22, and 10 (45%) of 22, respectively, for
infants with other pathogens; 27 (73%) of 37 infants who
tested positive for chlamydia had bilateral eye involvement
compared with 17 (77%) of 22 of infants with other patho-
gens. The presence of extraophthalmic symptoms did not
differ between infants with chlamydia and those with an-
other pathogen (Table 2). Feeding difficulties corresponded
with respiratory complications in infants who tested posi-
tive for chlamydia. In the other group, these were separate
cases. Additional symptoms in infants who tested positive
for chlamydia included rhinitis (12 of 37), cough (4 of 37),
excessive mucous (3 of 37), and wheezing or breathing
TABLE 1 Identiﬁed Pathogens Among Infants<3 Months of AgeWith Conjunctivitis
Pathogens Detected by
Test Method
Retrospective
Cohort
Prospective
Cohort
Total
Infants
Pa RR (95% CI)a
Bacterial culture, n 59 23 82
Staphylococcus aureus, n (%) 11 (19) 0 (0) 11 (13)
H inﬂuenzae, n (%) 5 (8) 2 (9) 7 (9)
Streptococcus pneumoniae, n (%) 4 (7) 0 (0) 4 (5)
N gonorrhoeae, n (%) 2 (3) 0 (0) 2 (2)
Other pathogens, n (%) 4 (7)b 3 (13)c 7 (9)
Cultures with pathogens, n (%)d 24 (41) 5 (22) 29 (35)
PCR 17 23 40
N gonorrhoeae, n (%) 1 (6) 0 (0) 1 (3)
PCR 42 23 65
C trachomatis, n (%) 27 (64) 14 (61) 41 (63) .001 1.8 (1.3–2.5)
RR indicates risk ratio; CI, conﬁdence interval.
a The P value is for the difference in the yield between the nonchlamydia pathogen culture (29 of 82) and C trachomatis PCR (41 of 65). RR reﬂects
the higher likelihood of ﬁnding chlamydia than another pathogen in these infants.
b Other pathogens includedMoraxella catarrhalis, Escherichia coli, Stenotrophomonas maltophilia, and hemolytic streptococcus.
c Other pathogens included 2M catarrhalis and 1 N meningitidis.
d Three coinfections included H inﬂuenzae, twice with N gonorrhoeae and once with S pneumoniae.
TABLE 2 Clinical Presentation of Neonatal Conjunctivitis by Causative Pathogen
Variable C trachomatis,
n (%)
Other Pathogens,
n (%)
Pa RR (95% CI)
Age at presentation 41 28 .03
1 wk 4 (10) 9 (32) 1.0 (Reference)
1 to 6 wk 34 (83) 15 (54) 2.3 (1.0–5.2)
6 wk 3 (7) 4 (14) 1.4 (0.4–4.5)
No. of symptoms 37 22 .26
1 symptom 8 (22) 9 (41) 1.0 (Reference)
MP discharge 7 (19) 9 (41)
Redness 1 (3) 0 (0)
2 symptoms 9 (24) 5 (23) 1.4 (0.7–2.6)
MP discharge swelling 6 (16) 3 (14)
MP discharge redness 2 (5) 2 (9)
Redness swelling 1 (3) 0 (0)
3 symptoms 20 (54) 8 (36) 1.5 (0.9–2.7)
MP discharge swelling redness
Extraophthalmic symptoms 37 20
Respiratory 14 (38) 6 (30) .55 1.3 (0.6–2.8)
Feeding 5 (14) 2 (10) .70 1.4 (0.3–6.4)
RR indicates risk ratio; CI, conﬁdence interval; MP, mucopurulent.
a The P value was for the test of heterogeneity of age or number of symptom categories; the P value of extraophthalmic symptoms was for the
difference between pathogen categories.
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difficulty (2 of 37 infants). In the group of infants with
other pathogens, 4 of 20 had rhinitis; 1 had cough, and 1
had wheezing and crepitations.
Therapy
Both GPs and ophthalmologists prescribed topical antibiot-
ics as eye ointment, gel, or drops, including tetracycline,
aminoglycosides with or without steroids (gentamicin, so-
framycin, or tobramycin), fusidic acid, polymyxin/tri-
methoprim, ofloxacin, and erythromycin. In addition, GPs
also prescribed chloramphenicol. Both GPs and ophthal-
mologists prescribed systemic treatment, including penicil-
lin, clarithromycin, and erythromycin. In addition, GPs
used cotrimoxazole and ophthalmologists used amoxicillin,
augmentin, flucloxacillin, and cefotaxime. Antibiotic treat-
ment by diagnosis as prescribed by GPs and ophthalmolo-
gists is shown in Table 3.
Comparison of treatment in the retrospective and
prospective cohorts showed that ophthalmologists gave
empiric antibiotics to 17 (63%) of 27 infants who tested
positive for chlamydia in the retrospective versus 14
(100%) of 14 in the prospective study (P  .01), anti-
chlamydial antibiotics to 14 (52%) of 27 and 7 (50%) of
14 infants (P .9), and systemic treatment to 6 (22%) of
27 and 1 (7%) of 14 infants, respectively (P  .22).
Follow-up
At follow-up, no more conjunctivitis was observed, and
no symptoms or signs of respiratory tract infection were
present.
DISCUSSION
This study demonstrated that C trachomatis was the major
cause of neonatal conjunctivitis in this population of
infants referred to pediatric or eye hospitals in Rotter-
dam. On clinical presentation, no distinction could be
made between chlamydial conjunctivitis and conjuncti-
vitis caused by other pathogens. Empiric management to
treat chlamydial conjunctivitis was frequently inappro-
priate.
The main limitation of this study was that we could
only include infants with conjunctivitis who were re-
ferred to specialist hospitals. Other limitations were the
incomplete diagnostic workup in the retrospective co-
hort and missing data on clinical symptoms in a few
infants. Also, the number of children in analyses was
relatively small, too small to draw firm conclusions.
Although we cannot show what proportion of all neo-
natal conjunctivitis is caused by C trachomatis, we have
shown that it is an important cause of (persistent) con-
junctivitis. Determining the incidence of chlamydial
neonatal conjunctivitis and transmission rates would re-
quire a prospective study testing all pregnant women
and their newborns.
The identification rate of pathogenic bacteria in our
study was 84%, which is higher than in most reports.17–20
In addition, C trachomatis was the organism isolated most
often. This is likely to be related to our study design and
to the Dutch referral system, in which mainly infants
with persistent conjunctivitis are referred to ophthal-
mologists. However, we may even have underestimated
the contribution of chlamydia to persistent neonatal
conjunctivitis, because we excluded the infants with a
clinical diagnosis of viral conjunctivitis. Underdiagnosis
of C trachomatis persistent conjunctivitis may also be
suggested by the relatively low observed number of 5
cases per year in the retrospective study versus 14 in the
prospective year. However, the latter increase may also
reflect an actual increase of chlamydial infection in
Dutch adults.21
To put our results into context, we related the find-
ings from our prospective study to obstetric data from
the SCH in that year. There were 1648 deliveries in total,
of which 731 were in women 30 years of age. With an
antenatal prevalence of 6.4%,16 47 women would be
expected to have C trachomatis infection. With an esti-
mated transmission rate of 50% to 75% and 20% to
50% of these developing conjunctivitis,5 we would ex-
pect 9 to 24 infants with chlamydial conjunctivitis,
which corresponds with our findings. This may suggest
that all of the infants with conjunctivitis were detected.
However, not all of the studied infants were born to
women delivering at the SCH, but also in other hospitals
in Rotterdam or at home.
The clinical presentation of chlamydial conjunctivitis
has been extensively described by others, and our study
shows similar results to previous reports.3,4,9,22–24 Most
infants who tested positive for chlamydia presented be-
tween the ages of 1 and 6 weeks (because of the slow
reproductivity of the organism) and with all 3 of the
symptoms (erythema, swelling, and discharge).
Ophthalmologists more often prescribed antibiotics
that were effective against chlamydial infection than
GPs. Still, only half of the infants with chlamydial con-
junctivitis received effective antibiotics before microbio-
logical diagnosis, and 20% received systemic treat-
ment. In the prospective study, even fewer infants
received systemic treatment. This probably reflects the
agreement made with ophthalmologists to refer infants
to a pediatrician after diagnosis. We cannot draw any
conclusions about chlamydial conjunctivitis in primary
health care from our study. Acute conjunctivitis may be
correctly treated by GPs with topical antibiotics accord-
ing to Health Care Insurance Board guidelines. However,
chlamydia is probably not being considered in the dif-
ferential diagnosis by some GPs, because only 12% of
infants with chlamydia had received antibiotics that
were active against C trachomatis.
TABLE 3 Antibiotic Treatment Prescribed by GPs and
Ophthalmologists
Antibiotic Treatment According
to Diagnosis
GPs, n/N
(%)
Ophthalmologists,
n/N (%)
Pa
Any conﬁrmed bacterial conjunctivitis
Any antibiotic 30/69 (43) 51/69 (74) .001
Chlamydia conjunctivitis
Any antibiotic 20/41 (49) 31/41 (76) .01
Antichlamydial antibiotic 5/41 (12) 21/41 (51) .0001
Systemic antichlamydial antibiotic 4/41 (10) 7/41 (17) .33
a The P value is for difference in treatment choice between GPs and ophthalmologists.
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Our results may suggest the need to institute eye
prophylaxis for ophthalmia neonatorum, which is not
practiced in the Netherlands. However, we do not want
to advocate the application of neonatal eye prophylaxis,
because prophylaxis does not prevent all chlamydial
neonatal conjunctivitis, and the absence of conjunctivitis
as an indicator of chlamydial infection may delay the
proper diagnosis of (silent) chlamydial infection at other
sites. Another motivation against the decision to start
routine eye prophylaxis is that this may lead to over-
treatment of newborns in a country with easy access to
medical care. We would rather like to use our findings to
indicate the need for proper (systemic) antibiotic treat-
ment of newborns who test positive for chlamydia and
screening of pregnant women.
Chlamydial screening for pregnant women is not
standard practice in the study area or in the rest of the
Netherlands. Testing is only done when clinically war-
ranted. In the prospective year of the study, only 1% of
1648 deliveries were tested for C trachomatis, of which 4
tested positive. These figures may also reflect the under-
estimation of chlamydial infection in pregnant women.
The value of screening may warrant additional discus-
sion.16 To prevent 1 case of chlamydial conjunctivitis, 31
to 78 pregnant women need to be screened. Assuming a
specificity of 99.8%,16 this could result in 0.06 to 0.16
false-positive mothers and 2 to 5 truly positive mothers
(and their partners); furthermore, this could result in the
prevention of 1.4 to 2.5 nasopharyngitis cases and 0.2 to
1.0 pneumonia cases. Previously we described the costs
of chlamydia screening of pregnant women by different
DNA-isolation methods in individual and pooled urine
samples.16 The cost per chlamydia case detected when
using the Cobas Amplicor on individual urine samples
was €275 and when using a combined method of iso-
lation with the MagNA Pure bacterial DNA-isolation
kit (Roche Molecular Diagnostics, Pleasanton, CA), and
subsequent amplification and detection by Cobas Ampli-
cor on pooled urine samples, as we did, was €108.
In the absence of a chlamydial screening program, we
urge clinicians to have a higher index of suspicion for
neonatal and maternal chlamydial infection. Further-
more, we recommend that, in areas where prenatal chla-
mydial screening and treatment of pregnant women is
not routine practice, infants with signs of conjunctivitis
that persist for 72 hours while applying frequent nor-
mal saline eye irrigation should have a full microbiolog-
ical evaluation including Neisseria gonorrhoeae and C tra-
chomatis. While awaiting laboratory results, empiric
treatment in this population should include erythromy-
cin eye drops or ointment to both eyes. We recommend
that confirmed chlamydial conjunctivitis should be
treated systemically with erythromycin suspension or
alternatively azithromycin.13,25
Current national treatment guidelines for neonatal
chlamydial conjunctivitis are from the Health Care In-
surance Board and recommend tetracycline eye drops
(with or without oral erythromycin or tetracycline).26
The current Centers for Disease Control and Prevention
recommendation, however, is to treat all neonatal chla-
mydial conjunctivitis systemically with a 14-day course
of erythromycin suspension.13 Systemic treatment has
been demonstrated to be more effective than topical
treatment, and infants with conjunctivitis are often in-
fected at other sites as well.27
CONCLUSIONS
The high rate of isolation of C trachomatis in infants with
persistent conjunctivitis confirms the importance of this
infection in the Netherlands. GPs and ophthalmologists
need to consider chlamydia in the differential diagnosis
of neonatal conjunctivitis and use appropriate antibiot-
ics. Targeted screening for C trachomatis prenatally to
prevent infection and related complications in both
mother and infants should again be considered in those
countries where it is not routine practice.
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